CD276 and neoplasm: Importantly, our IHC data showed that the combination of GSK3326595 and PD-1 blockade cooperatively decreased the Ki-67 and CD276 levels in MC38 tumor cells and increased the levels of TIIC-related markers, including CD3, CD8a, and GZMB (Fig. 7G and H), which indicate T-cell infiltration while preventing cytotoxicity, leading to improved tumor rejection.